Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirvetuximab soravtansine - ImmunoGen

Next Previous
Drug Profile

Mirvetuximab soravtansine - ImmunoGen

Alternative Names: Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853; ELAHERE; IMGN-853; M9346A-sSPDB-DM4; M9346A-sulfo-SPDB-DM4; MIRV; Mirvetuximab soravtansine-gynx

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer Hangzhou Zhongmei Huadong Pharmaceutical; ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Endometrial cancer; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 22 Mar 2024 US FDA grants full approval for mirvetuximab soravtansine for Ovarian Cancer, Fallopian tube cancer or Peritoneal cancer
  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 09 Feb 2024 City of Hope Comprehensive Cancer Center in collaboration with National cancer Institute completes a phase I trial in Ovarian cancer, Fallopian tube cancer, Endometrial cancer, Peritoneal cancer and Triple-negative-breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Recurrent) in USA (IV) (NCT02996825)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top